Abstract
Background: Alzheimer’s and Parkinson’s disease represent the two most common neurodegenerative disorders, affecting an increasing number of patients worldwide. Population ageing and lack of effective therapies and biomarkers strongly contribute to the socio-economical impact of these conditions.
Message and Conclusion: The aim of the review is to present a summary of the discoveries made on the epigenetics of Alzheimer’s and Parkinson’s disease, with a special focus on the recent advances towards the identification of new targeted therapies and biomarkers. Data supporting broad spectrum and selective small-molecule inhibition of enzymes controlling DNA methylation and histone modifications are discussed in the context of Alzheimer’s and Parkinson’s disease. The results obtained from studies performed on patients samples are also mentioned, to provide a picture of the efforts made toward identification of epigenetic-based biomarkers. Finally, given the importance of non-coding RNAs in neurodegeneration, their contribution to Alzheimer’s and Parkinson’s disease will be examined, together with a brief summary of the available miRNA-based biomarker signatures for these two conditions.Keywords: Epigenetic, Alzheimer's disease, Parkinson´s disease, histone acetylation, DNA methylation, histone modification, biomarker, targeted therapy.
Current Pharmaceutical Design
Title:Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies
Volume: 23 Issue: 5
Author(s): Filippo Ciceri, David Rotllant and Tamara Maes
Affiliation:
Keywords: Epigenetic, Alzheimer's disease, Parkinson´s disease, histone acetylation, DNA methylation, histone modification, biomarker, targeted therapy.
Abstract: Background: Alzheimer’s and Parkinson’s disease represent the two most common neurodegenerative disorders, affecting an increasing number of patients worldwide. Population ageing and lack of effective therapies and biomarkers strongly contribute to the socio-economical impact of these conditions.
Message and Conclusion: The aim of the review is to present a summary of the discoveries made on the epigenetics of Alzheimer’s and Parkinson’s disease, with a special focus on the recent advances towards the identification of new targeted therapies and biomarkers. Data supporting broad spectrum and selective small-molecule inhibition of enzymes controlling DNA methylation and histone modifications are discussed in the context of Alzheimer’s and Parkinson’s disease. The results obtained from studies performed on patients samples are also mentioned, to provide a picture of the efforts made toward identification of epigenetic-based biomarkers. Finally, given the importance of non-coding RNAs in neurodegeneration, their contribution to Alzheimer’s and Parkinson’s disease will be examined, together with a brief summary of the available miRNA-based biomarker signatures for these two conditions.Export Options
About this article
Cite this article as:
Ciceri Filippo, Rotllant David and Maes Tamara, Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies, Current Pharmaceutical Design 2017; 23 (5) . https://dx.doi.org/10.2174/1381612823666170124121140
DOI https://dx.doi.org/10.2174/1381612823666170124121140 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment
Current Medicinal Chemistry The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition
Current Medicinal Chemistry - Central Nervous System Agents Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Molecular Targeting of Breast Cancer: Molecular Imaging and Therapy
Current Pharmaceutical Biotechnology <i>Larrea tridentata</i> and its Biological Activities
Current Topics in Medicinal Chemistry Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry Tumor Bone Diseases: Molecular Mechanisms and Opportunities for Novel Treatments
Current Medicinal Chemistry - Anti-Cancer Agents Syntheses and Evaluation of Asymmetric Curcumin Analogues as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease
Current Alzheimer Research Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Meet Our Editorial Board Member
Letters in Drug Design & Discovery Design, Synthesis and Biological Evaluation of a Novel Series of Thiadiazole- Based Anticancer Agents as Potent Angiogenesis Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms
Current Pharmaceutical Design Dynamic Medicinal Chemistry in the Elaboration of Morphine-6- Glucuronide Analogs
Current Topics in Medicinal Chemistry Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets Amyloid-Degrading Enzymes as Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences